BiotechTube

HLA-A2 restricted glioma antigen peptides vaccine + Poly-ICLC

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Newly Diagnosed Pediatric Pontine Glioma

Conditions

Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma, Recurrent Pediatric High Grade Glioma, Recurrent Pediatric Low Grade Glioma

Trial Timeline

Feb 1, 2009 → Nov 1, 2024

NCT ID
NCT01130077

About HLA-A2 restricted glioma antigen peptides vaccine + Poly-ICLC

HLA-A2 restricted glioma antigen peptides vaccine + Poly-ICLC is a phase 1 stage product being developed by Brain Biotech for Newly Diagnosed Pediatric Pontine Glioma. The current trial status is completed. This product is registered under clinical trial identifier NCT01130077. Target conditions include Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma, Recurrent Pediatric High Grade Glioma.

What happened to similar drugs?

0 of 5 similar drugs in Newly Diagnosed Pediatric Pontine Glioma were approved

Approved (0) Terminated (1) Active (4)
🔄Olaparib 300mg tabletsAstraZenecaPhase 3
🔄Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3
🔄Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + DexamethasonePfizerPhase 3
❌Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3
🔄Bortezomib + Isatuximab + Iberdomide + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01130077Phase 1Completed

Competing Products

18 competing products in Newly Diagnosed Pediatric Pontine Glioma

See all competitors
ProductCompanyStageHype Score
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
Gliadel Wafer + TemozolomideEisaiPhase 2
31
Olaparib 300mg tabletsAstraZenecaPhase 3
44
PembrolizumabMerckPhase 2
39
Drug (including placebo)MerckPhase 1
21
CilengitideMerckPhase 2
31
[177Lu]Lu-NeoB + [68Ga]Ga-NeoBNovartisPhase 1
33
BKM120 + Trastuzumab + Paclitaxel + BKM120 PlaceboNovartisPhase 2
35
Tecentriq 1200 MG in 20 ML Injection + H3K27M peptide vaccineRochePhase 1
33
ZenapaxRochePhase 2
35
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3
47
Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + DexamethasonePfizerPhase 3
47
Elranatamab + Daratumumab + LenalidomidePfizerPhase 2
42
Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3
32
Bortezomib + Isatuximab + Iberdomide + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 3
47
Isatuximab-Irfc 20 MG/ML [Sarclisa] + Lenalidomide + Dexamethasone OralSanofiPhase 2
39
MebendazoleBrain BiotechPhase 1
19
Balstilimab + Botensilimab + Liposomal DoxorubicinAgenusPhase 2
32